69 related articles for article (PubMed ID: 32882019)
1. When CLL meets COVID-19.
Montserrat E
Blood; 2020 Sep; 136(10):1115-1116. PubMed ID: 32882019
[No Abstract] [Full Text] [Related]
2. Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients.
He J; Cai S; Feng H; Cai B; Lin L; Mai Y; Fan Y; Zhu A; Huang H; Shi J; Li D; Wei Y; Li Y; Zhao Y; Pan Y; Liu H; Mo X; He X; Cao S; Hu F; Zhao J; Wang J; Zhong N; Chen X; Deng X; Chen J
Protein Cell; 2020 Sep; 11(9):680-687. PubMed ID: 32671793
[No Abstract] [Full Text] [Related]
3. Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review.
Lin AY; Cuttica MJ; Ison MG; Gordon LI
EJHaem; 2020 Nov; 1(2):596-600. PubMed ID: 33043320
[TBL] [Abstract][Full Text] [Related]
4. Chronic Lymphocytic Leukemia Concomitant with COVID 19: A Case Report.
Ali E; Badawi M; Abdelmahmuod E; Kohla S; Yassin MA
Am J Case Rep; 2020 Oct; 21():e926062. PubMed ID: 33098641
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
6. Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia.
Dolan S; Christofides A; Doucette S; Shafey M
Curr Oncol; 2020 Aug; 27(4):e420-e432. PubMed ID: 32905290
[TBL] [Abstract][Full Text] [Related]
7. Vaccinations in CLL: implications for COVID-19.
Shadman M; Ujjani C
Blood; 2021 Jan; 137(2):144-146. PubMed ID: 33443562
[No Abstract] [Full Text] [Related]
8. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
9. Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience.
Wilde L; Isidori A; Keiffer G; Palmisiano N; Kasner M
Front Oncol; 2020; 10():1689. PubMed ID: 32984046
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: biological findings and therapeutic challenges.
Charra B; Ellouadghiri A; Magramane A; Kebbou T; Damaan K; Maghfour A; Seddiki K; Ezzouine H
Pan Afr Med J; 2020; 36():286. PubMed ID: 33117480
[TBL] [Abstract][Full Text] [Related]
11. Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute.
de Melo AC; Thuler LCS; da Silva JL; de Albuquerque LZ; Pecego AC; Rodrigues LOR; da Conceição MS; Garrido MM; Quintella Mendes GL; Mendes Pereira ACP; Soares MA; Viola JPB;
PLoS One; 2020; 15(10):e0241261. PubMed ID: 33104715
[TBL] [Abstract][Full Text] [Related]
12. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Cakir B
J Oncol Pharm Pract; 2020 Dec; 26(8):2068-2069. PubMed ID: 33081582
[No Abstract] [Full Text] [Related]
13. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Xia M; Luo TY; Shi Y; Wang G; Tsui H; Harari D; Spaner DE
J Immunol; 2020 Nov; 205(10):2629-2639. PubMed ID: 33067379
[TBL] [Abstract][Full Text] [Related]
14. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Agathangelidis A; Chatzidimitriou A; Gemenetzi K; Giudicelli V; Karypidou M; Plevova K; Davis Z; Yan XJ; Jeromin S; Schneider C; Pedersen LB; Tschumper RC; Sutton LA; Baliakas P; Scarfò L; van Gastel EJ; Armand M; Tausch E; Biderman B; Baer C; Bagnara D; Navarro A; Langlois de Septenville A; Guido V; Mitterbauer-Hohendanner G; Dimovski A; Brieghel C; Lawless S; Meggendorfer M; Brazdilova K; Ritgen M; Facco M; Tresoldi C; Visentin A; Patriarca A; Catherwood M; Bonello L; Sudarikov A; Vanura K; Roumelioti M; Skuhrova Francova H; Moysiadis T; Veronese S; Giannopoulos K; Mansouri L; Karan-Djurasevic T; Sandaltzopoulos R; Bödör C; Fais F; Kater AP; Panovska I; Rossi D; Alshemmari S; Panagiotidis P; Costeas P; Espinet B; Antic D; Foroni L; Montillo M; Trentin L; Stavroyianni N; Gaidano G; Francia di Celle P; Niemann C; Campo E; Anagnostopoulos A; Pott C; Fischer K; Hallek M; Oscier D; Stilgenbauer S; Haferlach C; Jelinek D; Chiorazzi N; Pospisilova S; Lefranc MP; Kossida S; Langerak AW; Belessi C; Davi F; Rosenquist R; Ghia P; Stamatopoulos K
Blood; 2021 Mar; 137(10):1365-1376. PubMed ID: 32992344
[TBL] [Abstract][Full Text] [Related]
15. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
16. A Case of COVID-19-Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?
Safarpour D; Srinivasan K; Farooqui M; Roth C; Ghouse M
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):69-72. PubMed ID: 33039356
[No Abstract] [Full Text] [Related]
17. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
Vijenthira A; Gong IY; Fox TA; Booth S; Cook G; Fattizzo B; Martín-Moro F; Razanamahery J; Riches JC; Zwicker J; Patell R; Vekemans MC; Scarfò L; Chatzikonstantinou T; Yildiz H; Lattenist R; Mantzaris I; Wood WA; Hicks LK
Blood; 2020 Dec; 136(25):2881-2892. PubMed ID: 33113551
[TBL] [Abstract][Full Text] [Related]
18. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J; de la Cruz J; Cedillo Á; Llamas P; Duarte R; Jiménez-Yuste V; Hernández-Rivas JÁ; Gil-Manso R; Kwon M; Sánchez-Godoy P; Martínez-Barranco P; Colás-Lahuerta B; Herrera P; Benito-Parra L; Alegre A; Velasco A; Matilla A; Aláez-Usón MC; Martos-Martínez R; Martínez-Chamorro C; Susana-Quiroz K; Del Campo JF; de la Fuente A; Herráez R; Pascual A; Gómez E; Pérez-Oteyza J; Ruiz E; Alonso A; González-Medina J; Martín-Buitrago LN; Canales M; González-Gascón I; Vicente-Ayuso MC; Valenciano S; Roa MG; Monteliu PE; López-Jiménez J; Escobar CE; Ortiz-Martín J; Diez-Martin JL; Martinez-Lopez J;
J Hematol Oncol; 2020 Oct; 13(1):133. PubMed ID: 33032660
[TBL] [Abstract][Full Text] [Related]
19. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
[TBL] [Abstract][Full Text] [Related]
20. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Pleyer C; Ali MA; Cohen JI; Tian X; Soto S; Ahn IE; Gaglione EM; Nierman P; Marti GE; Hesdorffer C; Lotter J; Superata J; Wiestner A; Sun C
Blood; 2021 Jan; 137(2):185-189. PubMed ID: 33259596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
